How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
First Trust Nasdaq Pharmaceuticals ETF (market value $1.2 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns. Returns to Oct 30, 2026.
What is your own portfolio exposed to? Check it with Exent →
Over the 5 years to Oct 30, 2026, First Trust Nasdaq Pharmaceuticals ETF (FTXH) returned +80.5% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 4.6 percentage points, or +12.5% a year against +12.0%.
| Period | FTXH | S&P 500 | FTXH per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | +47.8% | +12.0% | +47.8% | +12.0% | Beat |
| 3 years | +91.9% | +87.4% | +24.3% | +23.3% | Beat |
| 5 years | +80.5% | +75.9% | +12.5% | +12.0% | Beat |
| 10 years | +176.8% | +316.3% | +10.7% | +15.3% | Lagged |
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
FTXH beat the S&P 500 in 2 of the 9 full calendar years shown.
| Year | FTXH | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | +34.9% | +11.7% | +23.2% |
| 2025 | +24.2% | +17.7% | +6.5% |
| 2024 | +2.9% | +24.9% | −22.0% |
| 2023 | −1.4% | +26.2% | −27.6% |
| 2022 | +2.5% | −18.2% | +20.7% |
| 2021 | +6.1% | +28.7% | −22.6% |
| 2020 | +11.7% | +18.3% | −6.6% |
| 2019 | +22.2% | +31.2% | −9.0% |
| 2018 | −9.5% | −4.6% | −4.9% |
| 2017 | +19.4% | +21.7% | −2.3% |
Over 5 years, FTXH had a Sharpe ratio of 0.64 against 0.58 for the S&P 500, so it earned more return per unit of risk than the index. Its annualized volatility was 14.5% and its beta 0.45: it tended to move about 0.5× as much as the market.
| Metric | FTXH | S&P 500 |
|---|---|---|
| Annual return | +12.5% | +12.0% |
| Volatility (annualized) | 14.5% | 15.5% |
| Sharpe ratio | 0.64 | 0.58 |
| Sortino ratio | 1.09 | 0.91 |
| Max drawdown (month-end) | −12.9% | −23.9% |
| Beta to the S&P 500 | 0.45 | 1.00 |
FTXH was not trading through the earlier crises, so only its recent drawdowns are shown.
| Window | FTXH max drawdown |
|---|---|
| Last 1 year | −7.5% |
| Last 3 years | −19.5% |
| Last 5 years | −19.5% |
| Last 10 years | — |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, FTXH’s correlation with the S&P 500 was 0.48, with the Nasdaq‑100 0.26, with long Treasuries (TLT) 0.48 and with gold (GLD) 0.13.
Adding a 5% FTXH position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.1%.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| NET | −0.10 | JNJ | 0.78 |
| PLTR | −0.05 | AMGN | 0.67 |
| AMZN | −0.04 | ABBV | 0.63 |
| META | −0.02 | MRK | 0.63 |
| CRWD | −0.01 | PLD | 0.58 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
As of Oct 20, 2026, FTXH held 50 positions; its 10 largest made up 55.3% of the fund. The largest was ABBV (AbbVie Inc.) at 7.86%.
| Holding | Name | Weight |
|---|---|---|
| ABBV | AbbVie Inc. | 7.86% |
| LLY | Eli Lilly and Company | 7.65% |
| PFE | Pfizer Inc. | 7.38% |
| MRK | Merck & Co., Inc. | 6.93% |
| JNJ | Johnson & Johnson | 6.81% |
| VTRS | Viatris Inc. | 3.94% |
| BIIB | Biogen Inc. | 3.84% |
| GILD | Gilead Sciences, Inc. | 3.73% |
| ZTS | Zoetis Inc. | 3.68% |
| AMGN | Amgen Inc. | 3.52% |
From the fund’s latest published holdings. Overlap by weight adds up, for every stock both funds hold, the smaller of its two weights: 100% would mean the same portfolio. How much do VOO, QQQ and VTI overlap?
Exent matches every holding to the index with the most similar risk. For FTXH that is QQQ (the Nasdaq‑100). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
Ranked by how close each fund’s correlation with the S&P 500, the Nasdaq‑100, long Treasuries and gold, and its 5‑year volatility, came to FTXH’s (0.48 with the S&P 500, 17.0% volatility).
| Ticker | Name | Correlation with S&P 500 | 5‑year return | Volatility (5y) |
|---|---|---|---|---|
| IHE | iShares U.S. Pharmaceuticals ETF | 0.47 | +86.7% | 16.2% |
| XLU | State Street Utilities Select Sector SPDR ETF | 0.48 | +50.7% | 17.3% |
| XLV | State Street Health Care Select Sector SPDR ETF | 0.53 | +49.9% | 14.7% |
| IYH | iShares U.S. Healthcare ETF | 0.56 | +42.8% | 14.9% |
| VHT | Vanguard Health Care Index Fund ETF Shares | 0.59 | +42.5% | 14.9% |
| FDL | First Trust Morningstar Dividend Leaders Index Fund | 0.55 | +99.9% | 14.6% |
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Holdings and weights are the fund’s latest published holdings; ETF overlap compares those holdings stock by stock.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
No. FTXH returned +176.8% (+10.7% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.
Over the 5 years to Oct 30, 2026, FTXH’s Sharpe ratio was 0.64 and its Sortino ratio 1.09, versus 0.58 and 0.91 for the S&P 500.
FTXH’s 5‑year annualized volatility was 17.0%, lower than the S&P 500’s 17.0%, with a beta of 0.45.
Among large US stocks, the lowest correlations with FTXH over the last 60 months were NET (−0.10), PLTR (−0.05), AMZN (−0.04). Its correlation with long Treasuries (TLT) was 0.48 and with gold (GLD) 0.13.
Exent replays your whole portfolio through the same crashes, finds holdings that move together and compares you with a risk‑matched benchmark. Upload a screenshot; results in about a minute.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.